

DAFTAR PUSTAKA

- Al-Alem, E. & Curry, T. E. (2015). Ovarian Cancer: Involvement of the Matrix Metalloproteinase. *Reproduction*, 150(2): R55–R64.
- American Cancer Society. (2018). *Cancer Facts & Figures 2018*. Atlanta: American Cancer Society.
- American Cancer Joint Committee on Cancer. (2017). Ovary, Fallopian Tube, and Primary Peritoneal carcinoma. *AJCC Cancer Staging Manual*. 8th ed, 681-690.
- Aziz, M.F. (2009). Gynecological Cancer in Indonesia. *J. Gynecol Oncol.*, Mar, 20(1):8-10.
- Bakir, W. A., Latif, A. H., Ismail, N. H., Majeed, A.M. (2016). Detection and Clinical Correlation of mmp-7 in Breast Cancer Tissue. *Iraqi Med Jour*, 62(2):176-181.
- Barakat, R., Oakley, O., Kim, H., Jin, J., & Ko, C. J. (2016). Extra-gonadal sites of estrogen biosynthesis and function. *BMB reports*, 49(9), 488–496.
- Bedkowska, Gacuta E., Zajkowska *et al.* (2017). Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers. *Journal of Ovarian Research*, 10:39.
- Belli, C., Trapani D., Viale, G., D'amico, P., Duso, B. A. (2018). Targeting the microenvironment in solid tumors. *Cancer Treatment Reviews*, 65:22–32.
- Bio-Rad Laboratories, Inc. (2008). C1000TM Thermal Cycler Instruction Manual. [Online] Available from: http://www.bio-rad.com/webroot/web/pdf/lsr/literature/PN_10010305 [Accessed January 13th, 2019].
- Brun, J., Cortez, A., Lesieur, B., Uzan, S., Rouzier, R., Darai, E. (2012). Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer. *Onco Reports*, 27:1059-57.
- Caër, C., Rouault, C., Roy, T. L., Poitou, C., Aron-Wisnewsky, J., Torcivia, A., Bichet, J., Clément, K., Guerre-Millo, M., André, S. (2017). Immune cell-derived cytokines contribute to obesity-related inflammatin, fibrogenesis and metabolic deregulation in human adipose tissue. *Sci Reports*, 7(3000):1-11.
- Centers for Disease Control and Prevention and National Cancer Institute. (2018). U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on November 2017 submission data (1999-2015): U.S. Department of Health and Human Services. [Online] Available at: <https://gis.cdc.gov/Cancer/USCS/DataViz.html> [Accessed January 12th, 2019].
- Chang, L. C., Huang, C. F., Lai, M. S., et al. (2018). Prognostic factors in epithelial ovarian cancer: A population-based study. *PloS one*, 13(3), e0194993.
- Chen, J., Doyle, T. J., Liu, Y., Aggarwal, R., Wang, X., Shi, Y., et al. (2015). Biomarkers of rheumatoid arthritis-associated interstitial lung disease. *Arthritis & rheumatology (Hoboken, N.J.)*, 67(1):28–38.
- Choi, J., Wong, A. S. T., Huang, H., Leung, P. C. K. (2007). Gonadotropins and Ovarian Cancer. *Endocrine Reviews*, 28(4):440–61.
- Choi, K. C, Kang, S. K, Tai, C. J., Auersperg, N., Leung, P. C. (2002). Follicle-stimulating hormone activates mitogen-activated protein kinase in preneoplastic and neoplastic ovarian surface epithelial cells. *J Clin Endocrinol Metab* 87:2245–2253.
- Clark, D. P. (2019). *Molecular Biology*. 3th ed. Elsevier, pp 362-396.
- Cunningham, G., Leveno, K., Bloom, S., Spong, C., Hoffman, B., Casey, B., Sehfield, J. (2014). *Williams Obstetrics*. 24th ed. McGraw-Hill Education, pp 25-31.
- Curry, T. E. dan Osteen, K. G. (2003). The matrix metalloproteinase system: Changes, regulation and impact throughout the ovarian and uterine reproductive cycle. *Endocr Rev.*, Mar, 24(4):428-65.

- Dhitayoni, I. A. dan Budiana, I. N. G. (2017). Profil Pasien Kanker Ovarium di Rumah Sakit Umum Pusat Sanglah Denpasar - Bali Periode Juli 2013 - Juni 2014. *E-Jurnal Medika*, 6(3):1-9.
- Dirat, B., Bochet, L., Dabek, M., Daviaud, D., Dauvillier, S., Majed, B., Wang, Y.Y., Meulle, A., Salles, B., Le Gonidec, S., et al. (2011). Cancer associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. *Cancer Res* 71:2455–2465.
- DiSaia, P. J., Creasman, W., Mannel, R. S., McMeekin, D. S., Mutch, D. G. (2018). *Clinical Gynecologic Oncology*. 9th ed. Elsevier, pp. 253-289.
- Edfors, F., Danielsson F., Hallström B. M., Käll, L., Lundberg, E., Pontén F., Forsström B., Uhlén, M. (2016). Gene-specific correlation of RNA and protein levels in human cells and tissues. *Mol Syst Biol*, 12:883.
- Fathalla, M. F. (2013). Incessant ovulation and ovarian cancer – a hypothesis re-visited Facts. *Views Vis Obgyn*, 5(4):292–297.
- Franceschi, C & Campisi, J. (2014). Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases. *Jour of Geront: Biological Sci*, 69(S1):S4–S9.
- Gialeli, C., Theocharis, A. D., Karamanos, N. K. (2011). Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. *FEBS Journal*, 278:16–27.
- Gonzalez-Avila, G., Sommer, B., Mendoza-Posada, D. A., Ramos, C., Garcia-Hernandez, A. A., Falfan-Valencia R. (2019). Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer. *Critical Reviews in Oncology / Hematology*, 137:57–83.
- Goswami, S., Angkasekwinai, P., Shan, M., Greenlee, K. J., Barranco, W. T., Polikepahad, et al. (2009). Divergent functions for airway epithelial matrix metalloproteinase 7 and retinoic acid in experimental asthma. *Nature immunology*, 10(5):496–503.
- Grzechocińska, B., Dąbrowski, F., Cyganek, A., Panek, G., Wielgoś, M. (2017). The role of metalloproteinases in endometrial remodelling during menstrual cycle. *Ginekologia Polska*, 88(6):337-342.
- Grzechocińska, B., Dąbrowski, F., Sierdzinski, J., Cyganek, A., Wielgoś, M. (2019). The association between serum metalloproteinase concentration, obesity, and hormone levels in reproductive-aged women. *Endokrynologia Polska*, 70(I):49-56.
- Gründker, C., Günthert, A. R., Millar, R. P., Emons, G. (2002). Expression of Gonadotropin-Releasing Hormone II (GnRH-II) Receptor in Human Endometrial and Ovarian Cancer Cells and Effects of GnRH-II on Tumor Cell Proliferation. *Journ Clin Endocr & Metab*, Mar, 87(3):1427-30.
- Hagemann, T., Wilson, J., Burke, F., Kulbe, H., Li, N. F., Plüddemann, A., Charles K., Gordon, S., Balkwill, F. R. (2006). Ovarian Cancer Cells Polarize Macrophages Toward A Tumor-Associated Phenotype. *J Immunol*, 176:5023-5032
- Havrilesky, L. J., Moorman, P. G., Lowery, W. J., et al. (2013). Oral contraceptive pills as primary prevention for ovarian cancer: A systematic review and meta-analysis. *Obstet Gynecol*, 122:139-47.
- Horvath, L. E., Werner T., Boucher K., Jones K. (2013). The relationship between tumor size and stage in early versus advanced ovarian cancer. *Med Hypotheses*, 80:684-847.
- Huang, Z. Z, Gao, Y. T., Wen, W. Q., Li, H. L., Zheng, W., Shu, X. O., et al. (2015). Contraceptive methods and ovarian cancer risk among Chinese women: A report from the Shanghai Women's Health Study. *Int J Cancer*, 137: 607–14.

- Jordan, S. J., Siskind, V. C., Green, A., Whiteman, D. C., Webb, P. M. (2010). Breastfeeding and risk of epithelial ovarian cancer. *Cancer Causes Control*, Jan, 21(1):109-16.
- Kazantseva, M. G., Hung, N. A., Highton, J., Hessian, P. A. (2013). MMP expression in rheumatoid inflammation: the rs11568818 polymorphism is associated with MMP-7 expression at an extra-articular site. *Genes and Immunity*, 14:162-169.
- Kemendes RI. (2015). Situasi Penyakit Kanker. *Infodatin*. Jakarta: Pusat Data dan Informasi Kementerian Kesehatan RI.
- Kessenbrock, K., Plaks, V., Werb, Z. (2010). Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. *Cell*, 141:52-67.
- Koshiyama, M., Matsumur N., Konishi, I. (2014). Recent Concepts of Ovarian Carcinogenesis: Type I and Type II. *Biomed Res Intl*, 2014:1-11.
- Krakowiak, M. S., Noto, J. M., Piazuelo, M. B., Hardbower, D. M, Romero-Gallo, J., Delgado, A., Chaturvedi, R., Correa, P., Wilson, K. T., Peek, R. M. (2015). Matrix metalloproteinase 7 restrains Helicobacter pylori-induced gastric inflammation and premalignant lesions in the stomach by altering macrophage polarization. *Oncogene*, 34(14):1865-71.
- Kumar *et al.* (2018). Robbins Basic Pathology. 10th ed. Elsevier, pp 189-242.
- Kurman, R. J., Carcangiu, M. L., Herrington, C. S., Young, R. H. (2014). WHO Classification of Tumours of Female Reproductive Organs. IARC: Lyon, pp 11-83.
- Kurman, R. J., & Shih, I. (2016). The Dualistic Model of Ovarian Carcinogenesis Revisited, Revised, and Expanded. *Am J Pathol*, 186(4), 733–747.
- Lamouille, S., Xu, J., Derynck, R. (2014). Molecular mechanisms of epithelial–mesenchymal transition. *Nat Rev Mol Cell Biol*, 15(3): 178–196.
- Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., et al. (2016). Body Fatness and Cancer – Viewpoint of the IARC Working Group. *N Engl J Med*, 375:794-798.
- Laurent, L. C. dan Alexander, R. P. (2015). RNA isolation using the miRcury Biofluids Kit. *Protocol Exchange*. Springer Nature.
- Livak, K. J. and Schmittgen, T. D. (2001). Analysis of Relative Gene Expression Data Using Real- Time Quantitative PCR and the 2^{-ΔΔC_T} Method, 408, pp. 402–408.
- Lu. J. J., Zheng, Y., Kang, X., Yuan, J. M., Lauchlan, S. C., Pike, M. C., Zheng, W. (2000). Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. *Gynecol Oncol*, 79:158–168.
- McGuire, V., Hartge, P., Liao, L. M., Sinha, R., Bernstein, L., et al. (2016). Parity and Oral Contraceptive Use in Relation to Ovarian Cancer Risk in Older Women. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 25(7), 1059–1063.
- Meinhold-Heerlein, I., Fotopoulou, C., Harter, P. *et al.* (2015). Statement by the Kommission Ovar of the AGO: the new FIGO and WHO classification of ovarian, fallopian tube and primary peritoneal cancer. *Geburtshilfe Frauenheilkd*, Oct; 75(10):1021–1027.
- Miao, S., Zhou, S., Han, C., et al. (2015). Clinicopathological significance of matrix metalloproteinase-7 protein expression in esophageal cancer: a meta-analysis. *Drug Des Devel Ther*, 9:3729–3740.
- Mok, C. S., Kim, J. H., Skates, S. J., Schorge, J. O., Cramer, D. W., et al. (2017). Use of Blood-based mRNA profiling to Identify Biomarkers for Ovarian Cancer Screening. *Gynecol Obstet*, 7(6):1-7.
- Montes, A. F., Gómez, J. G., Viejo, M. N., Bermejo, M. A., Urrutia, S. A., Mata, J. G. (2012). Epidemiology and Etiology of Ovarian Cancer, *Ovarian Cancer - Basic*

- Science Perspective, Samir A. Farghaly (Ed.), InTech, [online] Available from: <https://www.intechopen.com/books/ovarian-cancer-basic-science-perspective/epidemiology-and-etiology-of-ovarian-cancer> [Accessed May 12th, 2019].
- Mutch, D., and Prat, J. (2014). Clinical Commentary: 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. *Gynecologic Oncology*, 133:401–404.
- Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod R., Zillhardt M. R., Romero, I. L., Carey, M. S., Mills, G. B., Hotamisligil, G. S., et al. (2011). Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. *Nat Med* 17:1498–1503.
- Nieto, M. A., Huang, RY-J., Jackson, R. A., et al. (2016). EMT: 2016. *Cell*, 166:21–45.
- Olsen, C. M., Nagle, C. M., Whiteman, D. C., Ness, R., Pearce, C. L., et al. (2013). Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. *Endocr Relat Cancer*, 20: 251–62.
- Pearce, C. L., Chung, K., Pike, M. C., Wu, A. H. (2009). Increased Ovarian Cancer Risk Associated with Menopausal Estrogen Therapy is Reduced by Adding a Progestin. *Cancer*, 115(3):531-539.
- Purdie, D. M., Bain, C. J., Siskind, V., Webb, P. M., Green, A. C. (2003). Ovulation and risk of epithelial ovarian cancer. *Int J cancer*, 104(2):228-32.
- Reid, B. M., Permuth, J. B., Sellers, T. A. (2017). Epidemiology of ovarian cancer: a review. *Cancer Biol Med*, 14(1): 9-32.
- Rohani, M. G. & Parks, W. C. (2015). Matrix remodeling by MMPs during wound repair. *Matrix Biol*, 113-121.
- Siegel, R., Ma, J., Zou, Z., Jemal, A. (2014). Cancer Statistics. *CA Cancer J. Clin*, 64(5):364.
- Sihombing, M., Sirait, A.M. (2007). Angka Ketahanan Hidup Penderita Kanker Ovarium di RS Or. Cipto Mangunkusumo. Jakarta, *Maj.Kedokt. Indon*, 57(10):346-52.
- Sung, H. K, Ma, S. H, Choi, J. Y, Hwang, Y., Ahn, C., Kim, B. G, et al. (2016). The effect of breastfeeding duration and parity on the risk of epithelial ovarian cancer: a systematic review and meta-analysis. *Journal of preventive medicine and public health*, 49(6):349-66.
- Syed, V., Ulinski, G., Mok, S. C., Yiu, G. K., Ho, S. (2001). Expression of gonadotropin receptor and growth responses to key productive hormones in normal and malignant human ovarian surface epithelial cells. *Cancer Research*, Sep, 61:6778-76.
- Thomas, H. (2017). MMP7 — a diagnostic biomarker for biliary atresia. *Nature Reviews Gastroenterology & Hepatology*, 15:68.
- Tognon, G., Carnazza, M., Ragnoli, M., Calza, S., Ferrari, F., Gambino, A., et al. (2013). Prognostic factors in early-stage ovarian cancer. *E-cancer Med Sci*, 7, 325.
- Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., Siegel, R. L. (2018). Ovarian Cancer Statistics. *CA Cancer J Clin*, 68:284–296.
- Tsilidis. K. K., Allen, N. E., Key, T. J., Dossus, L., Lukanova, A., Bakken, K., et al. (2011). Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. *Br J Cancer*, 105:1436–42.
- Wang, J., Lin, L., Parkash, V., Schwartz, P. E, Lauchlan, S. C, Zheng, W. (2003). Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary Müllerian systems. *Int J Cancer*, 103:328–334.

- Whittemore, A. S., Harris, R., Itnyre, J. (1992). Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. *Am J Epidemiol*, 136(10):1184-203.
- WHO expert consultant. (2004). Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet*, 363:157-163.
- Zhang, Y. & Cheng, Q. (2017). Relationship between matrix metalloproteinases and the occurrence and development of ovarian cancer. *Braz J Med Biol Res*, 50(6):e6104-12.
- Zhou, D., Tang, W., Liu, X., An, X., Zhang, Y. (2017). Clinical verification of plasma messenger RNA as novel noninvasive biomarker identified through bioinformatics analysis for lung cancer. *Oncotarget*, 8(27):43978-89.